Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Reina Sofia (25)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  3. Incidence of Diabetes Mellitus and Associated Factors in the Era of Antiretroviral Drugs With a Low Metabolic Toxicity Profile

    Open Forum Infectious Diseases, Vol. 11, Núm. 4

  4. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study

    eClinicalMedicine, Vol. 73

2023

  1. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2022

  1. Cancer Histology and Natural History of Patients with Lung Cancer and Venous Thromboembolism

    Cancers, Vol. 14, Núm. 17

  2. The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients

    Frontiers in Oncology, Vol. 12

2021

  1. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia

    Cancer, Vol. 127, Núm. 12, pp. 2003-2014

  2. Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 2, pp. 408-416

  3. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

  4. Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial

    Blood Advances, Vol. 5, Núm. 3, pp. 760-770

  5. PICO questions and DELPHI methodology for the management of venous thromboembolism associated with COVID-19

    Viruses, Vol. 13, Núm. 11

  6. The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial

    Cancers, Vol. 13, Núm. 10

2018

  1. Outcomes beyond the Third Month of Anticoagulation in Patients Aged >75 Years with a First Episode of Unprovoked Venous Thromboembolism

    TH Open, Vol. 2, Núm. 4, pp. e428-e436

2015

  1. Fondaparinux in the initial and long-term treatment of venous thromboembolism

    Thrombosis Research, Vol. 135, Núm. 2, pp. 311-317

  2. Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices?

    PLoS ONE, Vol. 10, Núm. 6

  3. The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry

    Thrombosis Journal, Vol. 13, Núm. 1

2012

  1. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

    Leukemia, Vol. 26, Núm. 7, pp. 1517-1526

2011

  1. Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family

    British Journal of Haematology, Vol. 155, Núm. 1, pp. 73-83

  2. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in Acute Lymphoblastic Leukemia

    PLoS ONE, Vol. 6, Núm. 2